Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA6 | P23280 | 3/20 | 0.33 |
| ▸ | CA5A | P35218 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675007 | 0.88 | DNM1 (0.44) | NFKB1CA12CA2CA4CA6 | |
| SCHEMBL16740665 | 0.80 | TRPV1 (0.39) | GSR | |
| SCHEMBL29203887 | 0.75 | TRPV1 (0.39) | CA12CA2CA4CA6CA5A | |
| SCHEMBL3817275 | 0.75 | CA12 (0.38) | CA12CA2CA4CA6CA5A | |
| SCHEMBL2026328 | 0.73 | OPRM1 (0.43) | CA2CA1DNM1TSHR | |
| SCHEMBL27767766 | 0.71 | — | — | |
| SCHEMBL721340 | 0.71 | OPRM1 (0.55) | LMNABLMCYP1A2THPOUBE2N | |
| SCHEMBL771021 | 0.69 | NFKB1 (0.43) | NFKB1CA12CA2CA4CA6 | |
| SCHEMBL937931 | 0.69 | — | — | |
| SCHEMBL238918 | 0.69 | NFKB1 (0.43) | NFKB1CA12CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7347984-B2 | Mammalian agmatinase inhibitory substance | JACKSON STATE UNIVERSITY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050220707-A1 | Mammalian agmatinase inhibitory substance | JACKSON STATE UNIVERSITY | 2005-10-06 | — | — | US | disclosed |
| US-5389707-A | Flame-retardant additives | MINISTERO DELL'UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1995-02-14 | — | — | US | disclosed |
| US-5344931-A | Salts of triazinic compounds with phosphorus oxyacids, and use of said compounds in self-extinguishing polymeric compositions | MINISTERO DELL'UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECHNOLOGICA (IT) | 1994-09-06 | — | — | US | disclosed |
| EP-0537837-A1 | Salts of triazinic compounds with phosphorus oxyacids, and use of said compounds in self-extinguishing polymeric compositions | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1993-04-21 | — | — | EP | disclosed |
| US-5104986-A | Polymeric flame retarders | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGIA (IT) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220707-A1 | Mammalian agmatinase inhibitory substance | ENGASE, DNPEP, GPI | NFKB1 3838/4885CA12 1668/4885CA2 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.